Emergent reversal of Vitamin K antagonists

Addressing all the factors

David T. Martin, Cassie A. Barton, Christopher Dodgion, Martin Schreiber

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Background Reversal of warfarin-induced coagulopathy after traumatic injury may be done exclusively with prothrombin complex concentrates (PCCs). No direct comparisons between different PCC regimens exist to guide clinical decision-making. Our institution has used 2 distinct PCC strategies for warfarin reversal; a 3-Factor PCC (Profilnine) combined with activated Factor VII (3F-PCC+rVIIa), and a 4-Factor PCC (Kcentra) given without additional factor supplementation. Methods Retrospective review of all PCC administrations to trauma patients with acute bleeding who were taking warfarin before injury. Primary endpoints were international normalized ratio (INR) reduction, in-hospital mortality, and diagnosis of deep venous thrombosis (DVT). Results Eighty-seven patients were identified from 2011 to 2015. Fifty-three were treated with 3F-PCC+rVIIa and 34 with 4F-PCC. Patient demographics, injury severity, and presenting laboratory data were similar. The 3F-PCC+rVIIa produced a lower median (IQR) INR postreversal compared with 4F-PCC (.75 (.69, 1.00) vs 1.28 (1.13, 1.36), P

    Original languageEnglish (US)
    Pages (from-to)919-925
    Number of pages7
    JournalAmerican Journal of Surgery
    Volume211
    Issue number5
    DOIs
    StatePublished - May 1 2016

    Fingerprint

    Vitamin K
    Warfarin
    International Normalized Ratio
    Wounds and Injuries
    prothrombin complex concentrates
    Factor VIIa
    Hospital Mortality
    Venous Thrombosis
    Demography
    Hemorrhage

    Keywords

    • Coagulopathy
    • Prothrombin complex concentrates
    • Traumatic hemorrhage
    • Warfarin

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Emergent reversal of Vitamin K antagonists : Addressing all the factors. / Martin, David T.; Barton, Cassie A.; Dodgion, Christopher; Schreiber, Martin.

    In: American Journal of Surgery, Vol. 211, No. 5, 01.05.2016, p. 919-925.

    Research output: Contribution to journalArticle

    Martin, David T. ; Barton, Cassie A. ; Dodgion, Christopher ; Schreiber, Martin. / Emergent reversal of Vitamin K antagonists : Addressing all the factors. In: American Journal of Surgery. 2016 ; Vol. 211, No. 5. pp. 919-925.
    @article{27e7a97d2a85424f93672098a0650a6d,
    title = "Emergent reversal of Vitamin K antagonists: Addressing all the factors",
    abstract = "Background Reversal of warfarin-induced coagulopathy after traumatic injury may be done exclusively with prothrombin complex concentrates (PCCs). No direct comparisons between different PCC regimens exist to guide clinical decision-making. Our institution has used 2 distinct PCC strategies for warfarin reversal; a 3-Factor PCC (Profilnine) combined with activated Factor VII (3F-PCC+rVIIa), and a 4-Factor PCC (Kcentra) given without additional factor supplementation. Methods Retrospective review of all PCC administrations to trauma patients with acute bleeding who were taking warfarin before injury. Primary endpoints were international normalized ratio (INR) reduction, in-hospital mortality, and diagnosis of deep venous thrombosis (DVT). Results Eighty-seven patients were identified from 2011 to 2015. Fifty-three were treated with 3F-PCC+rVIIa and 34 with 4F-PCC. Patient demographics, injury severity, and presenting laboratory data were similar. The 3F-PCC+rVIIa produced a lower median (IQR) INR postreversal compared with 4F-PCC (.75 (.69, 1.00) vs 1.28 (1.13, 1.36), P",
    keywords = "Coagulopathy, Prothrombin complex concentrates, Traumatic hemorrhage, Warfarin",
    author = "Martin, {David T.} and Barton, {Cassie A.} and Christopher Dodgion and Martin Schreiber",
    year = "2016",
    month = "5",
    day = "1",
    doi = "10.1016/j.amjsurg.2016.02.007",
    language = "English (US)",
    volume = "211",
    pages = "919--925",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - Emergent reversal of Vitamin K antagonists

    T2 - Addressing all the factors

    AU - Martin, David T.

    AU - Barton, Cassie A.

    AU - Dodgion, Christopher

    AU - Schreiber, Martin

    PY - 2016/5/1

    Y1 - 2016/5/1

    N2 - Background Reversal of warfarin-induced coagulopathy after traumatic injury may be done exclusively with prothrombin complex concentrates (PCCs). No direct comparisons between different PCC regimens exist to guide clinical decision-making. Our institution has used 2 distinct PCC strategies for warfarin reversal; a 3-Factor PCC (Profilnine) combined with activated Factor VII (3F-PCC+rVIIa), and a 4-Factor PCC (Kcentra) given without additional factor supplementation. Methods Retrospective review of all PCC administrations to trauma patients with acute bleeding who were taking warfarin before injury. Primary endpoints were international normalized ratio (INR) reduction, in-hospital mortality, and diagnosis of deep venous thrombosis (DVT). Results Eighty-seven patients were identified from 2011 to 2015. Fifty-three were treated with 3F-PCC+rVIIa and 34 with 4F-PCC. Patient demographics, injury severity, and presenting laboratory data were similar. The 3F-PCC+rVIIa produced a lower median (IQR) INR postreversal compared with 4F-PCC (.75 (.69, 1.00) vs 1.28 (1.13, 1.36), P

    AB - Background Reversal of warfarin-induced coagulopathy after traumatic injury may be done exclusively with prothrombin complex concentrates (PCCs). No direct comparisons between different PCC regimens exist to guide clinical decision-making. Our institution has used 2 distinct PCC strategies for warfarin reversal; a 3-Factor PCC (Profilnine) combined with activated Factor VII (3F-PCC+rVIIa), and a 4-Factor PCC (Kcentra) given without additional factor supplementation. Methods Retrospective review of all PCC administrations to trauma patients with acute bleeding who were taking warfarin before injury. Primary endpoints were international normalized ratio (INR) reduction, in-hospital mortality, and diagnosis of deep venous thrombosis (DVT). Results Eighty-seven patients were identified from 2011 to 2015. Fifty-three were treated with 3F-PCC+rVIIa and 34 with 4F-PCC. Patient demographics, injury severity, and presenting laboratory data were similar. The 3F-PCC+rVIIa produced a lower median (IQR) INR postreversal compared with 4F-PCC (.75 (.69, 1.00) vs 1.28 (1.13, 1.36), P

    KW - Coagulopathy

    KW - Prothrombin complex concentrates

    KW - Traumatic hemorrhage

    KW - Warfarin

    UR - http://www.scopus.com/inward/record.url?scp=84962013729&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84962013729&partnerID=8YFLogxK

    U2 - 10.1016/j.amjsurg.2016.02.007

    DO - 10.1016/j.amjsurg.2016.02.007

    M3 - Article

    VL - 211

    SP - 919

    EP - 925

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 5

    ER -